{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Table 2:', 'Schedule of Assessments: Part 1 of Study BCX7353-301', 'Assessment', 'Screening Period', 'Baseline', 'Part 1', 'Double-Blind, Placebo-Controlled Study Drug Administration', 'Screening Visita,b', 'Run-in', 'Day 1a', 'Week 2\u00b0', 'Week 4', 'Week 8', 'Week 12', 'Week 18', 'Week 24', '(up to Week -10)', 'Perioda', 'Day 15', 'Day 29', 'Day 57', 'Day 85', 'Day 127', 'Day 169d', '2 days', '2 days', '2 days', '2 days', '2 days', 'Informed consentb', 'X', 'In-clinic evaluation', 'X', 'X', 'Xc', 'X', 'X', 'X', 'X', 'X', 'Telephone contacte', 'Inclusion-exclusion criteria', 'X', 'X', 'X', 'Medical history', 'X', 'X', 'HAE medical and medication', 'X', 'history', 'Weight/height/BMIs', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Drugs of abuse screen', 'X', 'Physical examination\u00b9', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Pregnancy test\u00b9', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital signsk', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'FSH\u00b9', 'X', 'HIV, HCV, HBV serology', 'X', 'Diagnosis of HAE', 'X', 'establishedm', 'Angioedema events', 'X', 'eligibility determination', 'Safety laboratory', 'X', 'X', 'Xc', 'X', 'X', 'X', 'X', 'X', 'evaluationsh', 'Troponin I & troponin T', 'X', 'X', 'X', 'X', 'X', 'X', 'C1-INH antigenic level', 'X', 'C3', 'X', 'HLA typing\u00b0', 'X', 'Optional sample for possible', 'X', 'exploratory', 'pharmacogenomic testingp', 'NGAL', 'X', 'X', 'X', 'X', 'X', 'X', 'CK-MB', 'X', 'X', 'X', 'X', 'X', 'X', 'Urinalysish', 'X', 'X', 'Xc', 'X', 'X', 'X', 'X', 'X', '12-lead ECG9', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '55']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Assessment', 'Screening Period', 'Baseline', 'Part 1', 'Double-Blind, Placebo-Controlled Study Drug Administration', 'Screening Visita,b', 'Run-in', 'Day 1a', 'Week 2\u00b0', 'Week 4', 'Week 8', 'Week 12', 'Week 18', 'Week 24', '(up to Week -10)', 'Perioda', 'Day 15', 'Day 29', 'Day 57', 'Day 85', 'Day 127', 'Day 169d', '2 days', '2 days', '2 days', '2 days', '2 days', 'EQ-5D-5L', 'X', 'X', 'X', 'X', 'X', 'X', 'AE-QoL, TSQM, and WPAIs', 'X', 'X', 'X', 'X', 'X', 'X', 'Concomitant medications', 'AEs', 'Randomization', 'X', 'X', 'e-diary instruction/review/', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'set-up\"', 'e-diary completion', 'Study drug dosing\"', 'Investigator review of', 'angioedema events*', 'Study drug accountability/', 'X', 'X', 'X', 'X', 'X', 'X', 'dispensing', 'Plasma for PK and PD', 'X', 'X', 'X', 'X', 'X', 'X', 'analysisy', 'Abbreviations: AE = adverse event; AE-QoL = angioedema quality of life questionnaire; ALP = alkaline phosphatase; ALT = alanine transferase;', 'AST = aspartate aminotransferase; BMI = body mass index; C1-INH = C1 esterase inhibitor; C3 = complement 3; CK-MB = creatine kinase MB isoenzyme;', 'ECG = electrocardiogram; eCRF = case report form; e-diary = electronic diary; EQ-5D-5L = EuroQoI 5-dimensional, 5-level questionnaire; FSH = follicle', 'stimulating hormone; GGT = gamma-glutamyltransferase; HAE = hereditary angioedema; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human', 'immunodeficiency virus; HLA = human leukocyte antigen; IXRS = interactive (voice/Web) response system; NGAL = neutrophil gelatinase-associated', \"lipocalin; PD = pharmacodynamics; PK = pharmacokinetics; QTcF = QT interval corrected by Fridericia's formula; TSQM = Treatment Satisfaction\", 'Questionnaire for Medication; WPAI = Work Productivity and Activity Impairment Questionnaire.', 'a', 'The baseline visit must be held within 10 weeks (70 days) of the screening visit, accommodating a run-in period of 56 days. The investigator must gain', 'sponsor approval to enroll subjects who are not randomized within 10 weeks of the screening visit; this may require screening laboratory tests to be redrawn.', 'Subjects will not be permitted to rescreen if they did not meet the angioedema event requirements during the run-in period.', 'b', 'Signing of informed consent may occur in advance of the screening visit, which is defined as the visit where site-conducted screening procedures, including', 'e-diary dispensing, are performed.', 'c', 'The Week 2 visit will consist of monitoring liver function tests only (ALT, AST, GGT, total and direct bilirubin, ALP); urine and additional tubes of blood', 'will be required to accommodate possible reflex testing for abnormal GGT, AST, or ALT.', 'd', 'The last visit in Part 1 (Week 24) must occur the day following 24 weeks of study drug dosing in Part 1.', 'e', 'The investigator (or designee) must call and talk to the subject at least weekly in between the Screening and Baseline visits and on-treatment through', 'Week 24; alternative forms of interactive communication such as returned email and cellular text correspondence are acceptable. During all calls, the', \"investigator (or designee) will assess the subject's overall wellbeing, discuss compliance (if applicable), proper recording of angioedema event details\", '56']\n\n###\n\n", "completion": "END"}